Hexaxim Vaccine (tDAP) Immunization at Chughtai Lab

Hexaxim Vaccine (tDAP) at Chughtai Lab

The Hexaxim vaccine is a highly advanced, fully liquid, hexavalent (6-in-1) pediatric vaccine developed to protect infants and young children against six life-threatening infectious diseases. Administered as a single injection, it provides robust immunization against Diphtheria, Tetanus, Pertussis (whooping cough), Hepatitis B, Poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). While the term "tDAP" typically refers to the adolescent and adult booster vaccine for tetanus, diphtheria, and acellular pertussis, Hexaxim represents the primary pediatric counterpart (DTaP-IPV-HB-Hib) that establishes early-life immunity. Chughtai Lab, a premier diagnostic and healthcare network in Pakistan, offers this vital immunization service across its extensive network of medical centers, ensuring that infants receive world-class preventive care under strict clinical supervision.

Understanding the technology behind Hexaxim is essential for parents and healthcare providers. Unlike older, whole-cell pertussis vaccines that were associated with a higher incidence of post-vaccination fever and local reactions, Hexaxim utilizes an acellular pertussis (aP) component. This acellular formulation contains only highly purified, specific antigens of the Bordetella pertussis bacterium, which significantly reduces adverse reactions while maintaining exceptional immunogenicity. Additionally, the vaccine incorporates inactivated poliovirus (IPV) instead of the oral polio vaccine (OPV), eliminating the risk of vaccine-associated paralytic poliomyelitis. By combining six essential antigens into a single, ready-to-use liquid formulation, Hexaxim minimizes the number of injections an infant must receive, reducing physical discomfort, parental anxiety, and the clinical overhead associated with multiple visits.

The clinical importance of the Hexaxim vaccine cannot be overstated. In countries like Pakistan, where infectious diseases such as Hepatitis B, pertussis, and Hib-induced meningitis remain public health concerns, timely childhood vaccination is the most effective shield. The vaccine works by introducing harmless antigens into the infant's body, stimulating the immune system to produce specific antibodies and establish long-lasting immunological memory. Should the child encounter the actual pathogens in the future, their immune system is primed to rapidly neutralize the threat before clinical disease can develop. Chughtai Lab provides this vaccine in a highly controlled medical environment, adhering to international cold chain management standards to preserve vaccine potency from manufacturer to administration.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is key to ensuring a smooth, safe, and stress-free vaccination experience for both the infant and the parents. When scheduling a Hexaxim vaccination at Chughtai Lab, consider the following preparation guidelines:

• Bring the Vaccination Record: Always carry your child's official vaccination card or previous medical records to Chughtai Lab. This allows the healthcare professional to verify the immunization schedule and document the current dose accurately.
• Assess Current Health Status: Inform the clinical staff if your child has a fever, acute moderate-to-severe illness, or is undergoing any medical treatment. While a mild cold or low-grade fever is generally not a contraindication, severe acute illness may warrant postponing the vaccination.
• Disclose Medical History: Provide a comprehensive medical history, including any known allergies (especially to previous vaccines, neomycin, polymyxin B, or yeast), history of seizures, neurological disorders, or bleeding tendencies.
• Feed and Comfort: Feed your baby moderately before the appointment to prevent irritability. Dress the infant in loose, easily removable clothing to facilitate quick access to the injection site.
• Parental Comfort: Stay calm and reassuring. Infants can sense parental anxiety; maintaining a soothing tone and holding the child securely during the procedure significantly reduces distress.

During the Procedure

The administration of the Hexaxim vaccine at Chughtai Lab follows strict clinical protocols to ensure patient safety, comfort, and sterile delivery:

• Clinical Assessment: Before administration, a qualified healthcare professional or pediatrician will review the child's health status, confirm the correct vaccine dose, and inspect the vaccine vial for integrity and expiry.
• Patient Positioning: The infant is held securely by the parent or caregiver. For infants and toddlers, the preferred injection site is the anterolateral aspect of the thigh (vastus lateralis muscle), which provides a thick muscle mass free of major nerves and blood vessels.
• Aseptic Technique: The clinician cleanses the injection site thoroughly with an alcohol swab and allows it to air dry to prevent skin bacteria from entering the deep tissues.
• Intramuscular Injection: The Hexaxim vaccine is administered via a deep intramuscular injection at a 90-degree angle. The clinician uses a fine-gauge needle designed to minimize pain and tissue trauma.
• Immediate Post-Care: A sterile cotton ball is applied to the site with gentle pressure. Massaging the injection site is avoided as it can cause localized irritation.
• Observation Period: Parents are advised to remain in the Chughtai Lab waiting area for 15 to 30 minutes post-injection. This standard safety protocol allows medical staff to monitor the infant for any rare, immediate allergic reactions (anaphylaxis) and provide prompt medical intervention if necessary.

When is a Hexaxim Vaccine (tDAP) Performed?

Primary Infant Immunization Course

The primary clinical indication for the Hexaxim vaccine is the routine immunization of infants starting as early as 6 weeks of age. Pediatric guidelines, including those from the World Health Organization (WHO) and the Expanded Programme on Immunization (EPI) in Pakistan, recommend a primary series of three doses administered at 6, 10, and 14 weeks of age. This early schedule is critical because maternal antibodies decline rapidly after birth, leaving the infant highly vulnerable to devastating infections like pertussis and Haemophilus influenzae type b during the first few months of life.

Prevention of Pertussis (Whooping Cough) in Vulnerable Infants

Physicians strongly recommend Hexaxim to protect young infants from Bordetella pertussis, the causative agent of whooping cough. Pertussis is highly contagious and can lead to severe, spasmodic coughing fits, apnea, pneumonia, encephalopathy, and death in infants under six months of age. Because Hexaxim contains an acellular pertussis component, it provides high protective efficacy with a significantly lower risk of local reactions (such as swelling and pain) and systemic reactions (such as high fever) compared to older whole-cell pertussis vaccines.

Eradication of Poliomyelitis and Tetanus Protection

Hexaxim is administered to ensure continuous, reliable protection against Poliovirus types 1, 2, and 3, supporting global polio eradication efforts. It also protects against Clostridium tetani, a bacterium found in soil that can enter the body through minor cuts or umbilical cord stumps in newborns, causing neonatal tetanus—a disease characterized by severe muscle spasms and high mortality. The inactivated polio vaccine (IPV) component in Hexaxim induces systemic immunity without the risk of vaccine-derived paralytic polio, making it the preferred choice for modern pediatric care.

Early Protection Against Hepatitis B Virus

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Infants infected with Hepatitis B have a 90% risk of developing chronic, lifelong infections, which can ultimately lead to liver cirrhosis or hepatocellular carcinoma (liver cancer) in adulthood. Administering Hexaxim ensures that the child receives the necessary recombinant Hepatitis B surface antigen doses to build robust, lifelong protective antibody titers, stopping the transmission cycle early.

Prevention of Haemophilus influenzae type b (Hib) Infections

Haemophilus influenzae type b is a major cause of bacterial meningitis, pneumonia, epiglottitis, and septicemia in children under five years of age. Hib meningitis can cause permanent neurological damage, hearing loss, or learning disabilities. Clinicians prescribe Hexaxim because its conjugated Hib component (PRP-T) is highly immunogenic in young infants, stimulating the production of protective antibodies that have dramatically reduced the global burden of invasive Hib diseases.

What Does a Hexaxim Vaccine (tDAP) Detect?

As an immunization service rather than a diagnostic test, the Hexaxim vaccine does not "detect" active pathogens or diseases. Instead, it stimulates the human immune system to recognize, target, and neutralize specific antigenic structures. The clinical efficacy of the vaccine is measured by its ability to induce protective antibody titers against the following immunological targets and clinical conditions:

• Diphtheria Toxoid Antibodies: Stimulates neutralizing antibodies against the toxin produced by Corynebacterium diphtheriae, preventing pseudomembrane formation and systemic toxemia.
• Tetanus Toxoid Antibodies: Induces antibodies that neutralize the tetanospasmin neurotoxin produced by Clostridium tetani, preventing spastic paralysis.
• Pertussis Toxoid (PT) Antibodies: Targets the primary toxin of Bordetella pertussis, neutralizing its systemic and localized respiratory effects.
• Filamentous Haemagglutinin (FHA) Antibodies: Blocks the adhesion molecule used by Bordetella pertussis to bind to ciliated respiratory epithelial cells.
• Poliovirus Type 1 Neutralizing Antibodies: Prevents gastrointestinal replication and subsequent hematogenous spread of Poliovirus Type 1 to the central nervous system.
• Poliovirus Type 2 Neutralizing Antibodies: Establishes systemic immunity against Poliovirus Type 2, preventing paralytic poliomyelitis.
• Poliovirus Type 3 Neutralizing Antibodies: Provides targeted protection against Poliovirus Type 3-induced flaccid paralysis.
• Hepatitis B Surface Antibodies (anti-HBs): Induces protective titers (typically defined as ≥10 mIU/mL) against the outer envelope protein of the Hepatitis B virus, preventing acute and chronic hepatic infection.
• Haemophilus influenzae type b Capsular Polysaccharide (PRP) Antibodies: Targets the polyribosylribitol phosphate capsule of Hib, facilitating opsonization and phagocytosis of the bacteria.
• Prevention of Respiratory Diphtheria: Protects the upper respiratory tract from severe obstructive airway disease.
• Prevention of Cutaneous Diphtheria: Prevents localized, non-healing skin ulcers caused by toxigenic strains.
• Prevention of Neonatal Tetanus: Eliminates the risk of tetanus infection via the umbilical stump in early infancy.
• Prevention of Tetanus in Wounds: Provides systemic immunity against tetanus spores contaminating minor or major skin injuries.
• Prevention of Pertussis-Induced Apnea: Reduces the risk of life-threatening breathing pauses in infants.
• Prevention of Pertussis-Induced Encephalopathy: Protects against neurological complications resulting from severe whooping cough.
• Prevention of Vaccine-Associated Paralytic Polio (VAPP): Utilizes IPV to eliminate the risk of paralysis associated with oral polio vaccines.
• Prevention of Chronic Hepatitis B Carrier State: Blocks the establishment of persistent hepatic viral replication.
• Prevention of Hepatitis B-Induced Cirrhosis: Long-term prevention of chronic liver scarring.
• Prevention of Hepatocellular Carcinoma: Indirectly acts as a cancer-preventive vaccine by blocking chronic HBV infection.
• Prevention of Hib Bacterial Meningitis: Prevents inflammation of the protective membranes covering the brain and spinal cord.
• Prevention of Hib Epiglottitis: Prevents acute, life-threatening swelling of the epiglottis that can block the airway.
• Prevention of Hib Septicemia: Blocks systemic bloodstream infections and septic shock caused by Hib.
• Prevention of Hib Osteomyelitis and Arthritis: Prevents bacterial seeding of bones and joints in young children.
• Induction of Immunological Memory: Stimulates long-lived memory B and T lymphocytes for rapid secondary immune responses upon future pathogen exposure.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the documentation of your child's vaccination is handled with the utmost care and efficiency. Immediately following the administration of the Hexaxim vaccine, the clinical staff will update your child's physical vaccination card, noting the brand name (Hexaxim), batch number, manufacturer, date of administration, and the due date for the next dose. This physical record is crucial for future school admissions, international travel, and pediatric consultations.

In addition to the physical card, Chughtai Lab integrates all immunization records into its secure digital database. Parents can access their child's vaccination history and receipt of administration online through the official Chughtai Lab patient portal or the Chughtai Lab mobile application. This digital record is available almost immediately after the procedure, ensuring that you always have access to your child's health data, even if the physical card is misplaced. No waiting period or laboratory processing time is required, as vaccination is a direct clinical service rather than an analytical laboratory test.

Hexaxim Vaccine (tDAP) Findings Overview

Because Hexaxim is a preventive vaccine, the "findings" relate to the expected immunological responses, clinical observations, and potential post-vaccination reactions. The table below outlines the normal clinical expectations and potential abnormal responses that healthcare providers and parents should monitor:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Diphtheria Toxoid Protection	Seroprotection (antibody titers ≥ 0.1 IU/mL) within one month of completing the primary series.	Inadequate antibody response (titers < 0.1 IU/mL), requiring clinical evaluation or booster.
Tetanus Toxoid Protection	Seroprotection (antibody titers ≥ 0.1 IU/mL) indicating robust protection against tetanus toxin.	Failure to achieve protective titers, leaving the child vulnerable to tetanus infection.
Pertussis Protection (PT & FHA)	High vaccine response rate (four-fold increase in antibody titers post-vaccination).	Lack of significant antibody rise, which may occur in rare primary vaccine non-responders.
Poliovirus Protection (Types 1, 2, 3)	Neutralizing antibodies present against all three poliovirus serotypes, ensuring systemic immunity.	Absence of neutralizing antibodies to one or more serotypes (extremely rare).
Hepatitis B Protection (Anti-HBs)	Anti-HBs titer ≥ 10 mIU/mL, indicating complete protection against Hepatitis B virus.	Anti-HBs titer < 10 mIU/mL, which may require a booster dose or evaluation for non-responder status.
Hib Capsular Polysaccharide (PRP)	Anti-PRP antibody concentration ≥ 0.15 µg/mL (short-term) or ≥ 1.0 µg/mL (long-term protection).	Antibody concentration < 0.15 µg/mL, indicating insufficient protection against invasive Hib.
Injection Site Reaction	Mild redness, minor swelling (< 2.5 cm), and mild tenderness that resolve within 24 to 72 hours.	Severe localized swelling (> 5 cm), extensive redness, or abscess formation at the injection site.
Systemic Post-Vaccine Response	Mild, transient fever (< 38.5°C), slight irritability, or mild drowsiness that responds well to pediatric paracetamol.	High fever (≥ 40°C), persistent inconsolable crying lasting ≥ 3 hours, seizures, or anaphylactic shock.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Hexaxim Vaccine (tDAP)?

• Experienced Healthcare Professionals: Chughtai Lab employs highly trained, compassionate pediatric nurses and clinical staff who specialize in infant vaccination, ensuring a gentle and safe experience.
• Uncompromised Cold Chain Management: The efficacy of vaccines depends heavily on temperature control. Chughtai Lab utilizes state-of-the-art refrigeration and continuous temperature monitoring to ensure vaccines are stored exactly as required.
• Sourced Directly from Trusted Manufacturers: Chughtai Lab sources its vaccines, including Hexaxim, directly from certified global pharmaceutical manufacturers, guaranteeing authentic and high-quality products.
• Comprehensive Digital Records: All vaccinations are logged into the Chughtai Lab digital portal, allowing parents to access, download, and print their child's immunization history anytime, anywhere.
• Strict Sterile Protocols: The lab adheres to international infection control standards, utilizing single-use, sterile disposable syringes and maintaining a highly hygienic environment.
• Convenient Locations Across Pakistan: With an extensive network of diagnostic centers and medical clinics, Chughtai Lab makes it easy for families to access essential pediatric vaccines close to home.
• Patient-Focused Care: The clinic environments are designed to be welcoming and comfortable for infants and parents, minimizing the stress and anxiety often associated with medical visits.
• Integrated Healthcare Services: Beyond vaccinations, Chughtai Lab offers a complete suite of pediatric diagnostic tests, consultations, and wellness checks, providing a holistic approach to your child's health.